1. Home
  2. TOUR vs IMMP Comparison

TOUR vs IMMP Comparison

Compare TOUR & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tuniu Corporation

TOUR

Tuniu Corporation

HOLD

Current Price

$5.10

Market Cap

73.1M

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.44

Market Cap

61.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOUR
IMMP
Founded
2006
1987
Country
China
Australia
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.1M
61.4M
IPO Year
2014
2012

Fundamental Metrics

Financial Performance
Metric
TOUR
IMMP
Price
$5.10
$0.44
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
16.9K
439.9K
Earning Date
06-11-2026
05-12-2026
Dividend Yield
17.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.30
$445.09
Revenue Next Year
$14.00
N/A
P/E Ratio
$87.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$0.29
52 Week High
$7.79
$3.53

Technical Indicators

Market Signals
Indicator
TOUR
IMMP
Relative Strength Index (RSI) 46.45 51.93
Support Level $4.53 $0.42
Resistance Level $6.50 $0.56
Average True Range (ATR) 0.29 0.03
MACD 0.00 0.01
Stochastic Oscillator 40.17 74.89

Price Performance

Historical Comparison
TOUR
IMMP

About TOUR Tuniu Corporation

Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: